Back to Index
Tanya Dorff, MD
Associate Professor of Clinical Medicine
NOR 3457 Health Sciences Campus Los Angeles
+1 323 865 3905


Following a residency at Mt. Sinai Hospital in New York City, Dr. Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently teaches in the Division of Oncology at the Keck School of Medicine of USC, focusing on genitourinary cancers. In addition to being a devoted clinician and translational researcher, Dr. Dorff has authored more than 40 peer-reviewed articles as well as 35 review articles/commentaries. Dr. Dorff serves as associate editor for Clinical Genitourinary Cancer and Therapeutic Advances in Medical Oncology. She has lectured on the topic of prostate cancer for patients in both English and Spanish throughout California, and has presented her research at national meetings for oncologists. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and exercise during hormone therapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.


Keck School of Medicine of USC: Faculty Teaching Award, 2014

Keck School of Medicine of USC: Faculty Teaching Award, 2010

Fellowship Teaching Award

ACP/ASIM James R. Klinenberg: Certificate of Merit, 2000

AMWA Janet M. Glasgow Memorial: Achievement Citation, 2000

Medical Honors Society: AOA - Alpha Omega Alpha, 2000

National Merit Scholar


Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clin Genitourin Cancer. 2017 Mar 03. View in: PubMed

Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017 Feb 15; 9(377). View in: PubMed

Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series. BJU Int. 2016 Dec 15. View in: PubMed

A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis. 2016 Dec; 19(4):323-332. View in: PubMed

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clin Genitourin Cancer. 2016 Oct; 14(5):450-456. e1. View in: PubMed

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1317-24. View in: PubMed

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. J Clin Oncol. 2016 Jul 20; 34(21):2478-83. View in: PubMed

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016 Jun; 19(2):111-21. View in: PubMed

Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. View in: PubMed

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther. 2016; 9:5825-5837. View in: PubMed

Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. Front Pharmacol. 2016; 7:487. View in: PubMed

Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016; 16(1):360. View in: PubMed

Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57. View in: PubMed

Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urol Oncol. 2015 Aug; 33(8):341-2. View in: PubMed

A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab. 2015 Jul 7; 22(1):86-99. View in: PubMed

Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases. Oncology (Williston Park). 2015 Jun 15; 29(6). View in: PubMed

Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. 2015; 35:e270-3. View in: PubMed

Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. View in: PubMed

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. View in: PubMed

Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. Clin Genitourin Cancer. 2014 Dec; 12(6):440-6. View in: PubMed

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. View in: PubMed

New prostate cancer drugs: extending and improving life. Lancet Oncol. 2014 Sep; 15(10):1052-4. View in: PubMed

Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression. Cell Stem Cell. 2014 Jun 5; 14(6):810-23. View in: PubMed

Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. View in: PubMed

Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. Urol Oncol. 2014 May; 32(4):501-8. View in: PubMed

Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal. Clin Genitourin Cancer. 2014 Apr; 12(2):e55-8. View in: PubMed

Clinicopathologic Characteristics and Outcomes of Penile Cancer Treated at Tertiary Care Centers in the Western United States. Clin Genitourin Cancer. 2014 Apr; 12(2):138-42. View in: PubMed

Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. Urol Oncol. 2014 Jan; 32(1):52. e1-9. View in: PubMed

Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases. Urology. 2014 Jan; 83(1):159-66. View in: PubMed

Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan; 7(1):67-73. View in: PubMed

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014; 14:966. View in: PubMed

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. View in: PubMed

Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov; 31(8):1737-43. View in: PubMed

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. View in: PubMed

Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. Curr Opin Urol. 2013 Jul; 23(4):366-71. View in: PubMed

Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma. Oncology (Williston Park). 2013 Jul; 27(7):691-2, 694. View in: PubMed

Penile cancer: current therapy and future directions. Ann Oncol. 2013 May; 24(5):1179-89. View in: PubMed

Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus. Ann Oncol. 2013 Feb; 24(2):270-2. View in: PubMed

Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. View in: PubMed

Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol. 2013 Jan; 24(1):31-8. View in: PubMed

Small cell bladder cancer: biology and management. Semin Oncol. 2012 Oct; 39(5):615-8. View in: PubMed

Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. View in: PubMed

Blood cells and their use in active immunotherapy of prostate cancer. Hum Vaccin Immunother. 2012 Apr 1; 8(4):528-33. View in: PubMed

Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012 Mar; 109(6):846-54. View in: PubMed

Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012; 4(2):420-41. View in: PubMed

Ethnic differences in neuroendocrine expression in prostate cancer tissue. Anticancer Res. 2011 Nov; 31(11):3897-901. View in: PubMed

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. View in: PubMed

Use of testosterone replacement therapy in patients with prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):223-8. View in: PubMed

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5. View in: PubMed

Advanced prostate cancer: new agents, new questions. Oncology (Williston Park). 2011 May; 25(6):509, 512. View in: PubMed

The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist. 2011; 16(10):1349-58. View in: PubMed

Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010 Nov 15; 9(22):4474-6. View in: PubMed

The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate. 2010 Nov 1; 70(15):1692-700. View in: PubMed

Cabazitaxel in prostate cancer: stretching a string. Lancet. 2010 Oct 2; 376(9747):1119-20. View in: PubMed

Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coagul Fibrinolysis. 2010 Sep; 21(6):534-8. View in: PubMed

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 1; 16(11):3028-34. View in: PubMed

Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 2010 May; 105(10):1397-401. View in: PubMed

Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009 Dec; 1(12):988-1007. View in: PubMed

Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer. Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer. 2009 Nov 15; 115(22):5139-42. View in: PubMed

Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. View in: PubMed

Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009 Mar; 55(3):559-67. View in: PubMed

Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol. 2009 Feb; 27(1):39-44. View in: PubMed


Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. View in: PubMed

Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int. 2008 Nov; 102(9):1086-91. View in: PubMed

Diet and prostate cancer risk reduction. Expert Rev Anticancer Ther. 2008 Jan; 8(1):43-50. View in: PubMed

Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clin Genitourin Cancer. 2007 Jun; 5(5):344-6. View in: PubMed

Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Rev Anticancer Ther. 2006 Nov; 6(11):1639-51. View in: PubMed

Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology. 2006 Jun; 67(6):1247-52. View in: PubMed

Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology. 2005 May; 65(5):1008-12. View in: PubMed

Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer. 2005 Apr; 41(6):932-40. View in: PubMed

Powered bySC CTSI